EDMONTON, Oct. 16 /CNW/ - (ISA:TSX): Isotechnika Inc. today announced
that its medical device partner, Atrium Medical Corporation, presented new
data on its drug eluting coronary stent. Atrium presented the protocol design
for its CONFIRM 1 trial, a First-in-Man trial of its CINATRA(TM) product, a
drug eluting coronary stent coated with voclosporin. Atrium reported that the
trial has enrolled 69 of its targeted 100 patients at seven sites in Belgium,
and the Company expects to complete enrollment by the end of 2008. Data
collected thus far were presented at the 20th Annual Transcather
Cardiovascular Therapeutics (TCT) Conference held in Washington, DC from
October 12th to 17th. Isotechnika licensed voclosporin to Atrium Medical in
2005 for the exclusive use with implantable medical devices.
